{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:24:32Z","timestamp":1781155472078,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cefepime dosing guidelines are well defined in healthy populations but have not been studied extensively in critically ill children who often have significant alterations in antibiotic pharmacokinetics (PK) and pharmacodynamics (PD). Cefepime dosing optimization is important for patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We prospectively enrolled critically ill children receiving cefepime. Plasma samples were collected at opportunistic time points. Cefepime plasma concentrations were measured by liquid-chromatography-tandem mass spectrometry. Population PK (popPK) analysis was conducted with a priori selected covariates. The final covariate model was used to perform probability of target attainment (PTA) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 84 participants were analyzed. A 2-compartment with proportional error model was selected as the base model. Inclusion of weight and creatinine clearance (CrCl) improved model fit. Estimated breakpoints\u2014the highest minimum inhibitory concentration with \u226590% pharmacokinetic target attainment\u2014were 2-fold higher for 3-hour compared with 30-minute infusions for q8h dosing regimens. For q12h regimens, 3-hour infusions also yielded 2-fold higher breakpoints for the lowest target. Continuous compared with 3-hour infusions resulted in 4- to 16-fold higher breakpoints at the same daily dose at the higher targets. Increased CrCl led to reduced PTA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Given the variability observed in critically ill children, clinicians should consider incorporating therapeutic drug monitoring and popPK models to determine optimal dosing in this population. The use of extended infusions and more frequent or continuous dosing is beneficial for PK\/PD target achievement, particularly for Pseudomonas aeruginosa and antimicrobial-resistant pathogens. Use of these strategies should be strongly considered in the pediatric critically ill population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag069","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:45:02Z","timestamp":1770986702000},"source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetic Modeling and Target Attainment of Cefepime in Critically Ill Pediatric Patients"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-2222","authenticated-orcid":false,"given":"Stephanie L","family":"Rolsma","sequence":"first","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]},{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]},{"name":"Vanderbilt University School of Medicine , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9898-185X","authenticated-orcid":false,"given":"Marisa","family":"Blackman","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6849-6255","authenticated-orcid":false,"given":"Cole","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Dbouk","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4013-2572","authenticated-orcid":false,"given":"Foday","family":"Morovia","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Glover","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1329-7460","authenticated-orcid":false,"given":"Gabriella","family":"Ess","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2639-1396","authenticated-orcid":false,"given":"Katelyn","family":"Dohler","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2209-2121","authenticated-orcid":false,"given":"Brian","family":"Bridges","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatrics, Medical University of South Carolina , Charleston, South Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-7090","authenticated-orcid":false,"given":"Leena","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-9053","authenticated-orcid":false,"given":"C Buddy","family":"Creech","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]},{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]},{"name":"Vanderbilt University School of Medicine , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026022712563607100_ofag069-B1","doi-asserted-by":"crossref","first-page":"624639","DOI":"10.3389\/fped.2021.624639","article-title":"Model-informed precision dosing of antibiotics in pediatric patients: a narrative review","volume":"9","author":"Abdulla","year":"2021","journal-title":"Front Pediatr"},{"key":"2026022712563607100_ofag069-B2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/antibiotics10101182","article-title":"Pharmacokinetics of antibiotics in pediatric intensive care: fostering variability to attain precision medicine","volume":"10","author":"Gijsen","year":"2021","journal-title":"Antibiotics"},{"key":"2026022712563607100_ofag069-B3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1080\/17512433.2021.1961578","article-title":"Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations","volume":"14","author":"Tu","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026022712563607100_ofag069-B4","doi-asserted-by":"crossref","first-page":"818726","DOI":"10.3389\/fphar.2022.818726","article-title":"Characterizing pharmacokinetics in children with obesity-physiological, drug, patient, and methodological considerations","volume":"13","author":"Gerhart","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026022712563607100_ofag069-B5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2026022712563607100_ofag069-B6","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams","volume":"15","author":"Goncalves-Pereira","year":"2011","journal-title":"Crit Care"},{"key":"2026022712563607100_ofag069-B7","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s00134-014-3403-8","article-title":"Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med"},{"key":"2026022712563607100_ofag069-B8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00467-018-4120-2","article-title":"Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?","volume":"35","author":"Dhont","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"2026022712563607100_ofag069-B9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ccc.2017.06.005","article-title":"Pediatric extracorporeal membrane oxygenation","volume":"33","author":"Jenks","year":"2017","journal-title":"Crit Care Clin"},{"key":"2026022712563607100_ofag069-B10","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2016.07.169","article-title":"Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature","volume":"38","author":"Sherwin","year":"2016","journal-title":"Clin Ther"},{"key":"2026022712563607100_ofag069-B11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijantimicag.2017.02.025","article-title":"Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention","volume":"50","author":"Biffi","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2026022712563607100_ofag069-B12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/PCC.0b013e3181e28894","article-title":"Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults","volume":"12","author":"Bizzarro","year":"2011","journal-title":"Pediatr Crit Care Med"},{"key":"2026022712563607100_ofag069-B13","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1097\/CCM.0b013e318180fe62","article-title":"Antibiotic resistance\u2013what's dosing got to do with it?","volume":"36","author":"Roberts","year":"2008","journal-title":"Crit Care Med"},{"key":"2026022712563607100_ofag069-B14","doi-asserted-by":"crossref","first-page":"S642","DOI":"10.21037\/jtd.2017.11.02","article-title":"Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics","volume":"10","author":"Nardo","year":"2018","journal-title":"J Thorac Dis"},{"key":"2026022712563607100_ofag069-B15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026022712563607100_ofag069-B16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00745-20","article-title":"Population pharmacokinetics and target attainment of cefepime in critically ill patients and guidance for initial dosing","volume":"64","author":"Al-Shaer","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026022712563607100_ofag069-B17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/CCM.0000000000002817","article-title":"beta-lactam therapeutic drug management in the PICU","volume":"46","author":"Cies","year":"2018","journal-title":"Crit Care Med"},{"key":"2026022712563607100_ofag069-B18","doi-asserted-by":"crossref","first-page":"e0204621","DOI":"10.1128\/aac.02046-21","article-title":"Cefepime precision dosing tool: from standard to precise dose using nonparametric population pharmacokinetics","volume":"66","author":"Alshaer","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"key":"2026022712563607100_ofag069-B19","doi-asserted-by":"crossref","first-page":"1389.e1","DOI":"10.1016\/j.cmi.2022.05.007","article-title":"Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function","volume":"28","author":"de Cacqueray","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026022712563607100_ofag069-B20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1060028019865873","article-title":"Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: an update","volume":"54","author":"Hoff","year":"2020","journal-title":"Ann Pharmacother"},{"key":"2026022712563607100_ofag069-B21","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02006-18","article-title":"Cefepime pharmacokinetics in critically ill pediatric patients receiving continuous renal replacement therapy","volume":"63","author":"Stitt","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026022712563607100_ofag069-B22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/PCC.0000000000001786","article-title":"A population pharmacokinetic analysis to study the effect of extracorporeal membrane oxygenation on cefepime disposition in children","volume":"20","author":"Zuppa","year":"2019","journal-title":"Pediatr Crit Care Med"},{"key":"2026022712563607100_ofag069-B23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/INF.0000000000003371","article-title":"Pharmacokinetics of cefepime in children on extracorporeal membrane oxygenation: external model validation, model improvement and dose optimization","volume":"41","author":"Thibault","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"2026022712563607100_ofag069-B24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/PCC.0000000000003605","article-title":"Beta-lactam antibiotic exposure during pediatric extracorporeal membrane oxygenation: retrospective cohort analysis of drug levels using standard dosing, 2018\u20132020","volume":"25","author":"Marsaux","year":"2024","journal-title":"Pediatr Crit Care Med"},{"key":"2026022712563607100_ofag069-B25","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/jac\/dkad192","article-title":"Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy","volume":"78","author":"Pavia","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"August","key":"2026022712563607100_ofag069-B26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cca.2018.08.008","article-title":"Beta-lactam carryover in arterial and central venous catheters is negligible","volume":"486","author":"Marsh","year":"2018","journal-title":"Clin Chim Acta"},{"key":"2026022712563607100_ofag069-B27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2165\/00003088-199325020-00002","article-title":"Cefepime clinical pharmacokinetics","volume":"25","author":"Okamoto","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"2026022712563607100_ofag069-B28","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jac\/dkt523","article-title":"An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units","volume":"69","author":"Wong","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026022712563607100_ofag069-B29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of beta-lactam antibiotics","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"key":"2026022712563607100_ofag069-B30","first-page":"3178","article-title":"Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for?","volume":"70","author":"Huttner","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026022712563607100_ofag069-B31","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/phar.2844","article-title":"International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists: An executive summary","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2026022712563607100_ofag069-B32","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2026022712563607100_ofag069-B33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2125.2009.03591.x","article-title":"What is the right dose for children?","volume":"70","author":"Cella","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"2026022712563607100_ofag069-B34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/ACO.0000000000000810","article-title":"Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?","volume":"33","author":"Abdul-Aziz","year":"2020","journal-title":"Curr Opin Anaesthesiol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag069\/66923613\/ofag069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/2\/ofag069\/66923613\/ofag069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/2\/ofag069\/66923613\/ofag069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:56:49Z","timestamp":1772215009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag069\/8487311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag069","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2]]},"article-number":"ofag069"}}